Literature DB >> 22959317

Effects of fluoxetine on plasticity and apoptosis evoked by chronic stress in rat prefrontal cortex.

Ana Djordjevic1, Jelena Djordjevic, Ivana Elaković, Miroslav Adzic, Gordana Matić, Marija B Radojcic.   

Abstract

The prefrontal cortex is the brain region sensitive to detrimental effects of stress and even mild stress can rapidly impair its function. Aside from initiating proadaptive neuroplastic changes in the prefrontal cortex, chronic stress may also increase vulnerability of cortical neurons to apoptosis. Understanding the mechanism of plasticity and apoptotic processes is of immense importance for therapy of stress-related psychiatric disorders. In this study we tested whether molecular alterations in the prefrontal cortex, which occurred upon chronic social isolation, could be influenced by a prolonged fluoxetine treatment. We analyzed the expression of synaptic plasticity and apoptotic molecular markers in the prefrontal cortex of young-adult male Wistar rats exposed to 6-week social isolation with and without fluoxetine treatment during the last 3 weeks. Compartmental redistribution of NFκB transcription factor, involved in regulation of plasticity and apoptosis, was also examined. The level of synaptosomal polysialic neural cell adhesion molecule (PSA-NCAM) was increased in the prefrontal cortex of isolated rats as compared to untreated controls. Treatment with fluoxetine reduced the PSA-NCAM level only in isolated animals. In addition, mitochondrial Bax protein was elevated by chronic social isolation, while fluoxetine failed to abolish this effect. In spite of elevated Bcl-2 in the mitochondria, the calculated Bax/Bcl-2 ratio and concomitant absence of NFκB activation pointed to initiation of apoptotic signaling in the prefrontal cortex. The results imply that fluoxetine influences plasticity in the prefrontal cortex of chronically isolated rats and fails to prevent stress-induced initiation of apoptosis in this brain structure.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959317     DOI: 10.1016/j.ejphar.2012.07.042

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Targeting the Neuronal Activity of Prefrontal Cortex: New Directions for the Therapy of Depression.

Authors:  Xiao-Ting Zhou; Wen-Dai Bao; Dan Liu; Ling-Qiang Zhu
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

2.  Insufficiency of ventral hippocampus to medial prefrontal cortex transmission explains antidepressant non-response.

Authors:  Mariusz Papp; Piotr Gruca; Magdalena Lason; Ewa Litwa; Wojciech Solecki; Paul Willner
Journal:  J Psychopharmacol       Date:  2021-10-07       Impact factor: 4.153

Review 3.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

Review 4.  The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus.

Authors:  Steven R Wainwright; Liisa A M Galea
Journal:  Neural Plast       Date:  2013-04-09       Impact factor: 3.599

5.  Effects of doxepin on brain-derived neurotrophic factor, tumor necrosis factor alpha, mitogen-activated protein kinase 14, and AKT1 genes expression in rat hippocampus.

Authors:  Nastaran Eidelkhani; Maryam Radahmadi; Mohammad Kazemi; Laleh Rafiee; Hojjatallah Alaei; Parham Reisi
Journal:  Adv Biomed Res       Date:  2015-09-28

6.  Changes in apoptotic factors in hypothalamus and hippocampus after acute and subchronic stress induction during conditioned place preference paradigm.

Authors:  Abbas Haghparast; Zahra Fatahi; Shabnam Zeighamy Alamdary; Fariba Khodagholi
Journal:  EXCLI J       Date:  2013-12-04       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.